BioNTech (BNTX) on Oct. 6 said it formed a partnership between with the State of Victoria in Australia for research and development of potential mRNA-based vaccines and.
Announcing early clinical results from an ongoing Phase 1/2 trial, BioNTech (BNTX) said on Monday that its CAR-T cell therapy candidate, BNT211 showed a strong antitumor effect.